Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Up 555.7% in June

Posted by Geri Gentry on Jul 13th, 2026

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) saw a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 261,876 shares, an increase of 555.7% from the June 15th total of 39,939 shares. Based on an average trading volume of 1,319,031 shares, the short-interest ratio is currently 0.2 days. Approximately 15.1% of the company’s stock are sold short.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX stock traded down $0.28 on Monday, reaching $4.17. The stock had a trading volume of 19,451 shares, compared to its average volume of 165,009. The stock has a market cap of $8.38 million, a P/E ratio of -0.14 and a beta of 1.52. Quoin Pharmaceuticals has a 1 year low of $3.25 and a 1 year high of $41.80. The company has a 50 day simple moving average of $4.94 and a 200 day simple moving average of $7.46.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.17) by $0.40. On average, equities research analysts anticipate that Quoin Pharmaceuticals will post -7.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Ikarian Capital LLC purchased a new position in shares of Quoin Pharmaceuticals in the fourth quarter worth $3,052,000. Aberdeen Group plc bought a new position in Quoin Pharmaceuticals during the fourth quarter valued at $1,082,000. Millennium Management LLC purchased a new position in shares of Quoin Pharmaceuticals in the 4th quarter worth $1,080,000. SummitTX Capital L.P. bought a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth about $935,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth about $863,000. 8.63% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on QNRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Wednesday, April 22nd. ThinkEquity started coverage on shares of Quoin Pharmaceuticals in a research note on Monday, June 15th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Check Out Our Latest Report on QNRX

About Quoin Pharmaceuticals

(Get Free Report)

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.